Cellgram-LC is under clinical development by Pharmicell and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Cellgram-LC’s likelihood of approval (LoA) and phase transition for Liver Cirrhosis took place on 03 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cellgram-LC Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Livercellgram is under development for the treatment of alcoholic liver cirrhosis (decompensated cirrhosis). The therapy is administered through the hepatic artery. It comprises autologous bone marrow-derived mesenchymal stem cells (MSCs).
Pharmicell is a pharmaceutical company that discovers, develops and commercializes stem cell drugs. The company offers biochemical products and fine chemical products. Its product portfolio comprises cosmetics, hearty cellgram, nucleosides, PEG derivatives and flame retardants among others. Pharmicell offers services such as bone marrow banking and adult stem cell banking services.
Quick View Cellgram-LC LOA Data
|Highest Development Stage|